Search results for "XENOGRAFT"

showing 10 items of 161 documents

Carboxyamidotriazole-Orotate Inhibits the Growth of Imatinib-Resistant Chronic Myeloid Leukaemia Cells and Modulates Exosomes-Stimulated Angiogenesis

2012

The Bcr/Abl kinase has been targeted for the treatment of chronic myelogenous leukaemia (CML) by imatinib mesylate. While imatinib has been extremely effective for chronic phase CML, blast crisis CML are often resistant. New therapeutic options are therefore needed for this fatal disease. Although more common in solid tumors, increased microvessel density was also reported in chronic myelogenous leukaemia and was associated with a significant increase of angiogenic factors, suggesting that vascularity in hematologic malignancies is a controlled process and may play a role in the leukaemogenic process thus representing an alternative therapeutic target. Carboxyamidotriazole-orotate (CTO) is …

MaleResearch ValidityPhysiologyAngiogenesisTumor PhysiologyFusion Proteins bcr-ablCancer Treatmentlcsh:MedicinePharmacologyExosomesCardiovascular PhysiologyBiochemistryPiperazinesHematologic Cancers and Related DisordersMicechemistry.chemical_compoundCell Movementhemic and lymphatic diseasesMolecular Cell BiologyBasic Cancer ResearchMedicine and Health SciencesPhosphorylationPost-Translational ModificationExtracellular Signal-Regulated MAP Kinaseslcsh:ScienceChronic Myelogenous LeukemiaMultidisciplinaryABLNeovascularization PathologicGene Expression Regulation LeukemicChemistryHematologyResearch AssessmentOncologyBenzamidesImatinib MesylateMedicineOncology AgentsAntiangiogenesis Therapymedicine.drugResearch ArticleChronic Myeloid LeukemiaAntineoplastic AgentsResearch and Analysis MethodsCell GrowthCell Line TumorLeukemia Myelogenous Chronic BCR-ABL PositiveLeukemiasCell AdhesionHuman Umbilical Vein Endothelial CellsmedicineAnimalsHumansRNA MessengerPhosphotyrosineBiologyCell ProliferationOrotic AcidTumor microenvironmentCarboxyamidotriazoleInterleukin-8lcsh:RBiology and Life SciencesProteinsCancers and NeoplasmsImatinibTriazolesmedicine.diseaseXenograft Model Antitumor AssaysRetractionExosomePyrimidinesImatinib mesylateDrug Resistance NeoplasmCarboxyamidotriazole Orotatelcsh:QAngiogenesisCell Adhesion MoleculesProto-Oncogene Proteins c-aktDevelopmental BiologyChronic myelogenous leukemiaPLoS ONE
researchProduct

Treating cachexia using soluble ACVR2B improves survival, alters mTOR localization, and attenuates liver and spleen responses.

2018

Background Cancer cachexia increases morbidity and mortality, and blocking of activin receptor ligands has improved survival in experimental cancer. However, the underlying mechanisms have not yet been fully uncovered. Methods The effects of blocking activin receptor type 2 (ACVR2) ligands on both muscle and non‐muscle tissues were investigated in a preclinical model of cancer cachexia using a recombinant soluble ACVR2B (sACVR2B‐Fc). Treatment with sACVR2B‐Fc was applied either only before the tumour formation or with continued treatment both before and after tumour formation. The potential roles of muscle and non‐muscle tissues in cancer cachexia were investigated in order to understand th…

MaleTUMOR-BEARING MICElcsh:Diseases of the musculoskeletal systemCachexiaprotein synthesisActivin Receptors Type IIMDSCphysical activityAcute phase responseKaplan-Meier EstimateACTIVATIONActivinMiceNeoplasmsOrthopedics and Sports MedicineTOR Serine-Threonine Kinasesactivinlcsh:Human anatomyII RECEPTORSRecombinant ProteinsProtein TransportLivermyostatinPROTEIN-SYNTHESISSKELETAL-MUSCLECytokinessyöpätauditInflammation MediatorsACUTE-PHASE RESPONSE3122 CancersINHIBITIONlcsh:QM1-695acute phase responsePhysiology (medical)Cell Line TumorAnimalsHumansMuscle SkeletalActivin; Acute phase response; MDSC; Myostatin; Physical activity; Protein synthesis; Orthopedics and Sports Medicine; Physiology (medical)Physical activityMyeloid-Derived Suppressor CellsMyostatinXenograft Model Antitumor AssaysDisease Models AnimalACTIVIN-APHYSICAL-ACTIVITY3121 General medicine internal medicine and other clinical medicineproteiinitEXPERIMENTAL CANCER CACHEXIAlcsh:RC925-935Protein synthesislihassurkastumasairaudetBiomarkersSpleenJournal of cachexia, sarcopenia and muscle
researchProduct

Effects of small interfering RNAs targeting fascin on human esophageal squamous cell carcinoma cell lines

2010

Abstract Background Fascin induces membrane protrusions and cell motility. Fascin overexpression was associated with poor prognosis, and its downregulation reduces cell motility and invasiveness in esophageal squamous cell carcinoma (ESCC). Using a stable knockdown cell line, we revealed the effect of fascin on cell growth, cell adhesion and tumor formation. Methods We examined whether fascin is a potential target in ESCC using in vitro and in vivo studies utilizing a specific siRNA. We established a stable transfectant with downregulated fascin from KYSE170 cell line. Results The fascin downregulated cell lines showed a slower growth pattern by 40.3% (p In vivo, the tumor size was signific…

MaleTime FactorsHistologyEsophageal NeoplasmsMice NudeApoptosismacromolecular substancesCysteine Proteinase InhibitorsBiologyTransfectionAmino Acid Chloromethyl KetonesPathology and Forensic MedicineExtracellular matrixMiceDownregulation and upregulationCell Line TumorCell Adhesionlcsh:PathologyAnimalsHumansRNA Small InterferingCell adhesionCell ProliferationFascinMice Inbred BALB CCell growthResearchMicrofilament ProteinsGeneral MedicineTransfectionCaspase InhibitorsXenograft Model Antitumor AssaysTumor BurdenCell biologyCell cultureApoptosisCaspasesCarcinoma Squamous Cellbiology.proteinRNA InterferenceCollagenCarrier Proteinslcsh:RB1-214Diagnostic Pathology
researchProduct

The Role of Immunohistochemistry in Rhabdomyosarcoma Diagnosis Using Tissue Microarray Technology and a Xenograft Model

2015

Rhabdomyosarcomas (RMS) may resemble other non-myogenic sarcomas and malignant rhabdoid tumor (MRT). Alveolar rhabdomyosarcoma (ARMS) often harbors a typical translocation, but embryonal rhabdomyosarcoma (ERMS) lacks any specific rearrangement. Histopathology is not always sufficient for an unequivocal diagnosis, necessitating ancillary studies, including immunohistochemistry (IHC). Sixteen genetically tested RMS and two MRT were xenografted and followed in successive passages. Tissue microarrays were constructed including samples from original and xenograft tumors. Desmin, myogenin, CK, EMA, INI1, LSD1, AP2 beta, fibrillin-2, HMGA2, nestin, and SIRT1 were tested using immunohistochemical s…

Malemusculoskeletal diseasesmedicine.medical_specialtyPathologygenetic structuresMice NudeBiologyPathology and Forensic MedicineDiagnosis DifferentialMiceRhabdomyosarcomaBiomarkers TumormedicineAnimalsHumansRhabdomyosarcomaRhabdoid TumorTissue microarraytissue microarraysGeneral MedicineNestinmedicine.diseasemusculoskeletal systemImmunohistochemistryDisease Models AnimalxenograftsTissue Array AnalysisPediatrics Perinatology and Child HealthimmunohistochemistryAlveolar rhabdomyosarcomaCancer researchHeterograftsImmunohistochemistryHistopathologyDesminEmbryonal rhabdomyosarcomarhabdomyosarcoma
researchProduct

Influence of the use of autogenous bone particles to close the access window after maxillary sinus floor augmentation: an experimental study in rabbi…

2020

Abstract Aim To study the influence on the healing of the placement of particulate autogenous bone in the antrostomy and in the subjacent region after maxillary sinus elevation. Material and methods Sixteen New Zealand rabbits were undergone to bilateral maxillary sinus floor augmentation with 4 × 4 mm antrostomy dimension. The sinus mucosa was elevated, and the space obtained was filled with xenograft. In the test site (treated sites), autogenous bone was harvested from the tibia and was placed either in the antrostomy and the subjacent region while the control site was left untreated. Antrostomy was covered bilaterally with collagen membranes. Animals were euthanized after 1 and 8 weeks o…

Maxillary sinusCollagen membranelcsh:MedicineDentistry03 medical and health sciences0302 clinical medicineStatistical significanceMedicineBone formationTibiaAutogenous boneSinus (anatomy)Test sitebusiness.industryResearchXenograftlcsh:RCollagen membraneOsteoconductivity030206 dentistrylcsh:RK1-715medicine.anatomical_structureSinus floor elevationlcsh:Dentistry030220 oncology & carcinogenesisAutogenous bonebusinessInternational Journal of Implant Dentistry
researchProduct

Tuning gut microbiota through a probiotic blend in gemcitabine‐treated pancreatic cancer xenografted mice

2021

Medicine (General)Transplantation HeterologousMedicine (miscellaneous)Gut floraSettore MED/08 - Anatomia PatologicaDeoxycytidineLetter to Editorlaw.inventionProbioticMiceR5-920lawPancreatic cancermedicineAnimalsbiologybusiness.industryProbioticsbiology.organism_classificationmedicine.diseaseGemcitabineGemcitabineGastrointestinal Microbiomegut microbiota gemcitabine pancreatic cancer xenografted micePancreatic NeoplasmsCancer researchMolecular Medicinebusinessmedicine.drugClinical and Translational Medicine
researchProduct

Impact of hypoxia on chemoresistance of mesothelioma mediated by the proton-coupled folate transporter, and preclinical activity of new anti-LDH-A co…

2020

Abstract Background Expression of proton-coupled folate transporter (PCFT) is associated with survival of mesothelioma patients treated with pemetrexed, and is reduced by hypoxia, prompting studies to elucidate their correlation. Methods Modulation of glycolytic gene expression was evaluated by PCR arrays in tumour cells and primary cultures growing under hypoxia, in spheroids and after PCFT silencing. Inhibitors of lactate dehydrogenase (LDH-A) were tested in vitro and in vivo. LDH-A expression was determined in tissue microarrays of radically resected malignant pleural mesothelioma (MPM, N = 33) and diffuse peritoneal mesothelioma (DMPM, N = 56) patients. Results Overexpression of hypoxia…

MesotheliomaCancer ResearchPleural NeoplasmsCell Culture TechniquesPemetrexedDeoxycytidineArticle03 medical and health sciencesMice0302 clinical medicinelactate dehydrogenase inhibitorsIn vivoAntigens NeoplasmCell Line TumormedicineGene silencingAnimalsHumansMesotheliomaEnzyme InhibitorsCarbonic Anhydrase IXPeritoneal Neoplasms030304 developmental biology0303 health sciencesL-Lactate DehydrogenaseCell growthChemistryhypoxiaMesothelioma MalignantDrug SynergismHypoxia (medical)Translational researchmedicine.diseaseSettore CHIM/08 - Chimica FarmaceuticaXenograft Model Antitumor AssaysGemcitabineGemcitabineCell HypoxiaGene Expression Regulation NeoplasticPemetrexedOncologyDrug Resistance Neoplasm030220 oncology & carcinogenesisPeritoneal mesotheliomaCancer researchFemalemedicine.symptomProton-Coupled Folate Transportermedicine.drugBritish journal of cancer
researchProduct

Safety of a 3-weekly schedule of carboplatin plus pegylated liposomal doxorubicin as first line chemotherapy in patients with ovarian cancer: prelimi…

2006

Abstract Background The MITO-2 (Multicentre Italian Trials in Ovarian cancer) study is a randomized phase III trial comparing carboplatin plus paclitaxel to carboplatin plus pegylated liposomal doxorubicin in first-line chemotherapy of patients with ovarian cancer. Due to the paucity of published phase I data on the 3-weekly experimental schedule used, an early safety analysis was planned. Methods Patients with ovarian cancer (stage Ic-IV), aged 2, every 3 weeks or to carboplatin AUC 5 plus pegylated liposomal doxorubicin 30 mg/m2, every 3 weeks. Treatment was planned for 6 cycles. Toxicity was coded according to the NCI-CTC version 2.0. Results The pre-planned safety analysis was performed…

OncologyCancer Researchendocrine system diseasesSettore MED/06 - Oncologia Medicamedicine.medical_treatmentPACLITAXELlaw.inventionPolyethylene Glycolschemistry.chemical_compoundRandomized controlled trialSTAGE-IIIlawCYCLOPHOSPHAMIDEAntineoplastic Combined Chemotherapy ProtocolsOvarian NeoplasmsSTERICALLY STABILIZED LIPOSOMESMiddle Agedlcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensCombined Modality Therapyfemale genital diseases and pregnancy complicationsPaclitaxelOncologyMITO-2 randomized trialcarboplatinSURVIVALFemaleChemical and Drug Induced Liver Injurymedicine.drugAgranulocytosisResearch ArticleAdultmedicine.medical_specialtyCARCINOMAOvariectomylcsh:RC254-282Drug Administration ScheduleDrug HypersensitivityCISPLATINpreliminary resultInternal medicinemedicineGeneticsXENOGRAFTSHumansDoxorubicinParesthesianeoplasmsMETAANALYSISAgedChemotherapybusiness.industryAlopeciamedicine.diseasePHASE-IIIThrombocytopeniaCarboplatinSurgeryClinical trialchemistryDoxorubicinLiposomesFeasibility StudiesTopotecanOvarian cancerbusinessBMC Cancer
researchProduct

Tumorigenic and metastatic activity of human thyroid cancer stem cells

2010

Abstract Thyroid carcinoma is the most common endocrine malignancy and the first cause of death among endocrine cancers. We show that the tumorigenic capacity in thyroid cancer is confined in a small subpopulation of stem-like cells with high aldehyde dehydrogenase (ALDHhigh) activity and unlimited replication potential. ALDHhigh cells can be expanded indefinitely in vitro as tumor spheres, which retain the tumorigenic potential upon delivery in immunocompromised mice. Orthotopic injection of minute numbers of thyroid cancer stem cells recapitulates the behavior of the parental tumor, including the aggressive metastatic features of undifferentiated thyroid carcinomas, which are sustained by…

OncologyMaleCancer ResearchLung NeoplasmsPapillaryNudeMessengerThyroid GlandFluorescent Antibody TechniqueTYROSINE KINASEMice SCIDCell TransformationImmunoenzyme TechniquesMiceMice Inbred NODCell MovementAdenocarcinoma FollicularThyroid cancerRADIOACTIVE IODINETumor Stem Cell AssayEPITHELIAL-MESENCHYMAL TRANSITION; ALDEHYDE DEHYDROGENASE-ACTIVITY; ACUTE MYELOID-LEUKEMIA; RADIOACTIVE IODINE; TYROSINE KINASE; LUNG-CANCER; CARCINOMA; RECEPTOR; GROWTH; DIFFERENTIATIONBlottingReverse Transcriptase Polymerase Chain ReactionThyroidMiddle AgedProto-Oncogene Proteins c-metFlow CytometryEPITHELIAL-MESENCHYMAL TRANSITIONmedicine.anatomical_structureCell Transformation NeoplasticDIFFERENTIATIONOncologyNeoplastic Stem CellsAdenocarcinomaGROWTHFemaleStem cellWesternAdultmedicine.medical_specialtyBlotting WesternMice NudeACUTE MYELOID-LEUKEMIABiologyAdenocarcinomaSCIDALDEHYDE DEHYDROGENASE-ACTIVITYThyroid carcinomaYoung AdultLUNG-CANCERAdenocarcinoma Follicular; Adult; Aged; Aldehyde Dehydrogenase; Animals; Blotting Western; Carcinoma; Carcinoma Papillary; Case-Control Studies; Cell Adhesion; Cell Movement; Cell Proliferation; Cell Transformation Neoplastic; Female; Flow Cytometry; Fluorescent Antibody Technique; Humans; Immunoenzyme Techniques; Lung Neoplasms; Male; Mice; Mice Inbred NOD; Mice Nude; Mice SCID; Middle Aged; Neoplasm Invasiveness; Neoplastic Stem Cells; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-met; RNA Messenger; Reverse Transcriptase Polymerase Chain Reaction; Thyroid Gland; Thyroid Neoplasms; Tumor Stem Cell Assay; Xenograft Model Antitumor Assays; Young Adult; Cancer Research; OncologyCancer stem cellSettore MED/04 - PATOLOGIA GENERALEInternal medicinemedicineCell AdhesionAnimalsHumansNeoplasm InvasivenessRNA MessengerThyroid NeoplasmsALDH Human Thyroid Cancer Stem CellsAgedCell ProliferationNeoplasticRECEPTORCarcinomaFollicularTumor Stem Cell AssayCancerAldehyde Dehydrogenasemedicine.diseaseXenograft Model Antitumor AssaysCarcinoma PapillaryCase-Control StudiesInbred NODRNAProto-Oncogene Proteins c-akt
researchProduct

Development of primary human NSCLC patient derived xenograft and organoids models as a precision approach to tumor treatment

2018

Oncologymedicine.medical_specialtyOncologybusiness.industryInternal medicineOrganoidMedicineTumor therapyHematologybusinessTumor xenograft
researchProduct